After aducanumab failure, Eisai to test another anti-amyloid mAb

With the announcement that Eisai plans to start yet another Phase III trial of an anti-amyloid candidate, Alzheimer's disease researcher Rudolph Tanzi told BioCentury he wouldn't enroll any more AD patients in trials of therapies based on the amyloid hypothesis.

The latest trial start came just one day after Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) said they would discontinue the Phase III ENGAGE and EMERGE trials and two other studies of aducanumab, a mAb against β amyloid (see "Biogen's Lead Balloon")...